Image Courtesy: Shutterstock
Chinese researchers have unveiled an AI-powered drug discovery platform capable of screening massive libraries of chemical compounds in seconds, potentially transforming how new medicines are developed during both routine research and global health emergencies.
The platform, called GalaxyVS, was developed using China’s next-generation Tianhe supercomputers and is designed to dramatically accelerate the early stages of drug discovery. Researchers say the system can analyze molecular interactions at speeds up to one million times faster than existing supercomputing molecular docking methods, according to the South China Morning Post.
The breakthrough was announced by the National Supercomputing Centre in Tianjin, which collaborated with researchers from Tsinghua University and its Institute for AI Industry Research. The team integrated a virtual screening framework known as DrugCLIP, an ultra-fast AI model previously detailed in the journal Science earlier this year.
Drug screening is typically one of the most time-consuming phases of pharmaceutical development. Researchers often spend months or even years testing how potential compounds interact with disease targets before identifying viable lead molecules. By compressing that process into seconds, systems like GalaxyVS could significantly reduce research costs and accelerate timelines for new treatments.
Developers say the platform could help identify therapies for cancers, neurodegenerative disorders, rare diseases, and emerging infectious diseases. The speed advantage may also prove valuable during future public health crises where rapid drug discovery becomes critical.
The announcement also highlights China’s growing investment in AI-driven scientific infrastructure and supercomputing capabilities. Over the past several years, Chinese institutions have increasingly focused on combining large-scale computing power with machine learning models to compete globally in biotechnology and pharmaceutical innovation.
The pharmaceutical industry has been aggressively exploring AI-assisted drug development in recent years, with companies worldwide racing to automate molecular analysis, protein modeling, and clinical prediction workflows. While AI systems still require extensive experimental validation in real-world laboratories, researchers believe these platforms could drastically improve efficiency during the earliest stages of medicine development.
